Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
AQST Transcript
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary and Q&A reveal strong financial performance, strategic product development, and promising market strategies. Anaphylm's launch preparation and international expansion plans are positive indicators, supported by stable financials and a robust cash position. The Q&A highlights management's proactive approach to market challenges and confidence in regulatory timelines, despite some uncertainties. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. The FDA approval and launch of Anaphylm, along with international expansion plans, suggest potential growth. However, financial guidance shows a significant EBITDA loss, and there are uncertainties regarding FDA meetings and protocol modifications. The Q&A reveals positive sentiment from the allergist community and readiness for regulatory requirements, but management's vague responses on certain issues raise concerns. Overall, the combination of positive development plans and financial challenges results in a neutral sentiment.
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
AQST Slides
AQST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
